We caught up with speakers and presenters at a major HIV community meeting to learn how HIV care providers can uncover and remove the harm of bias in their work.
This week, a study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis (PrEP).
"Overall, we saw improvements for the whole population, suggesting that the efforts to test [and] diagnose HIV infection sooner, start [antiretroviral] treatment earlier and help patients be retained in care and adherent to their treatment are workin...
Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.
Paul Sax, M.D., provides a quick rundown of what he considers the most interesting studies presented at this year's Conference on Retroviruses and Opportunistic Infections.
If an HIV-positive patient's viral load test results come back between 50 copies/mL and 200 copies/mL, consider retesting the same blood sample, Joseph Eron Jr., M.D., recommends. New study results suggest that the retest results may alter a clinicia...
High-dose, long-term omega-3 supplementation appears to yield improved triglycerides and C-reactive protein levels among HIV-positive people who have elevated triglycerides, but only after more than a year of use, a new study has found.
Virological Response Without Routine Viral Load Monitoring in Children: Results From the ARROW Trial
Reassuring virological outcomes without routine viral load monitoring shown in the ARROW trial but viral rebound greater than 5000 copies/mL should prompt switch to second-line, according to data presented 8th International Workshop on HIV Paediatric...
The Swiss HIV Cohort Study presented additional data at this year's International AIDS Conference showing that life expectancy has increased another 34 years for a person who is on HIV treatment and in care.
Starting ART in primary compared to chronic HIV infection had a significantly higher chance of getting a CD4:CD8 ratio >1.0 in a retrospective study in which individuals were their own controls.